Drug Profile
CSG GD2
Alternative Names: CSG-GD2Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator CARsgen
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neuroblastoma
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Neuroblastoma in China (Parenteral) (CARsgen pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Neuroblastoma in China (Parenteral)
- 09 Aug 2016 Preclinical trials in Neuroblastoma in China (Parenteral)